Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

FDA clears Pfizer’s leukaemia drug Besponsa

The breakthrough treatment is the first CD22-targeted ADC to be approved in the US

- PMLiVE

emotive appoints head of talent

Adela Zafar moves from NAVBLUE to take up the newly-created role

- PMLiVE

Lynparza approval sets up tighter bout with PARP rivals

US regulator gives AZ the go-ahead for a new maintenance indication and formulation

- PMLiVE

Does your content have enough content?

Finding the balance in health and science communications

- PMLiVE

Communicating beyond the data

Relying on alternative methods to deliver results

- PMLiVE

Insights are our digital media bag

Life at Four Health Media has been pretty busy this last 12 months. We have a new name (we were previously Four MSA), our team has grown, we have new...

Four Agency Worldwide

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

- PMLiVE

Trump disbands CEO councils after more defections

J&J’s Gorsky resigns following Trump's remark about Charlottesville

US health reforms

Is the stage set for price controls in the US?

- PMLiVE

Uniting around a common goal

The importance of the multidiscipline team

- PMLiVE

Baird Capital backs Prescient Healthcare Group

Group invests in the consultancy by dipping into its $310m fund

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links